Wedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $34
Vera Therapeutics, Inc. Class A
Vera Therapeutics, Inc. Class A VERA | 0.00 |
Wedbush analyst Laura Chico maintains Vera Therapeutics (NASDAQ:
VERA) with a Neutral and lowers the price target from $43 to $34.
